Our mission is to advance groundbreaking academic discoveries to preclinical studies in order to demonstrate their relevance in blocking disease initiation and progression.
All TDI projects begin with a groundbreaking research discovery by a member of the Tri-I community. A researcher who has identified a disease target that might lead to a novel drug can seek drug development support through TDI.
At TDI, we apply the best modern medicinal chemistry techniques and technologies to our projects, through partnerships with our academic and industrial collaborators.
Over the course of the partnership, TDI oversees all aspects of the drug discovery process. By providing industry-level support for each academic project, we can rapidly assess the therapeutic potential of the research discovery.
A key feature of TDI is that the academic investigators and their host institutions retain control over all intellectual property generated in the execution of a project.
Common Roadblock: Without expert assistance in navigating the path of drug discovery, even the most transformational research advances often do not realize their potential to become major medical breakthroughs.
Removing the barriers that impede academic drug discovery. TDI connects researchers from Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine with collaborators from across the globe to remove the barriers that impede drug discovery in academic settings. Together with our partner, Takeda, we enable the discovery of next-generation drugs by empowering our faculty with the tools, technology, and expertise to meet this extraordinary challenge.
Our academic researchers excel at discovering new biological pathways that are responsible for disease initiation and progression. However, the chasm between these biological insights and impact on patients can seem overwhelming. In order to effectively translate novel insights into drugs, academic scientists must have access to cutting-edge drug discovery tools, technologies, and expertise.
TDI's primary role in the community is to provide the bridge between basic academic discovery and real-world application. At TDI, we provide industry-quality drug development support for each project in our portfolio. We leverage the resources of our three institutions, our industry partner, Takeda Pharmaceuticals, and a global network of collaborators to help our academic partners rapidly advance their groundbreaking discoveries along the path from bench to bedside.